Jackson Center, PA, May 17, 2021 – Halberd Corporation (OTC-PINK: “HALB“) announces the successful conjugation of gold-coated iron nanoparticles with Halberd’s patent-pending monoclonal antibody against the SARS-CoV-2 spike protein.  This milestone paves the way for testing to proceed on the elimination of disease through the application of extracorporeal radio frequency waves or laser emissive energy to bodily fluids of infected patients.

Dr. Mitchell S. Felder, Halberd Corporation’s Chief Technical Officer stated, “Although we were successful earlier in conjugating solid gold nanoparticles with Halberd’s patent-pending monoclonal antibody, we found that the gold was not sufficiently reactive to the radiowaves to accomplish the efficient eradication of the disease antigen.  Iron oxide nanoparticles are the ideal metal for this process. Unfortunately, we were unable to create a stable conjugation of the iron oxide with our patent-pending antibody.  The gold-coated iron nanoparticle, by contrast, provides the combination of traits to satisfy both conditions:

  1. Sufficiently reactive to radio waves and laser emissive energy, and
  2. The ability to facilitate a stable conjugation.

Our patented extracorporeal approach to treatments is a necessary element to the eradication of disease through radiofrequency waves and laser emissive energy.”

William A. Hartman, Halberd’s Chairman, President & CEO, commented, “We commend the ingenuity and persistence of our team to seek a viable solution.  We now have a road to success with the appropriate combination of metallic properties for the disease eradication process. This discovery was only possible with the careful study and testing by Dr. Qiang Chen of GreenBioAZ.  With a suitable conjugation methodology achieved, we can now proceed with proof-of-concept testing at Youngstown State University (YSU) using E. coli as a first step.  After successful completion of testing at YSU, pathogenic virus testing at a secure Level 3 laboratory will be conducted under the direct supervision of Dr. Chen and the GreenBioAZ team, at the Arizona State University facility.”

To get the latest news on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
https://halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.

Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements.  It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies:

­­­Title Patent/
Application No. 		Filing Date Status/Document
*Method for Treating and Curing Covid-19 Infection US 62/989981 03/16/2020 Provisional
PCT/US21/22541 03/16/2021 International  PCT
*Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients US 63/007207 04/08/2020 Provisional
Covid-19 Inflammatory Cytokine Storm Treatment PCT/US21/26386 04/08/2021 International PCT
*Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus US 63/013104 04/21/2020 Provisional
Treating and Curing Covid-19 Infection Utilizing a Laser PCT/US21/28368 04/21/2021 International PCT
*Method For The Rapid Identification Of Covid-19 Infection US 63/049441 07/08/2020 Provisional
*Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans US 63/080735 09/20/2020 Provisional
*Nasal Spray To Prevent The Transmission Of The Covid-19 Virus US 63/108301 10/31/202 Provisional
*Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus US 63/111043 11/08/2020 Provisional
*Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus) US 63/135695 01/10/2021 Provisional

Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates made by management.  Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.